(Q51680781)

English

Growth factor and patient-adapted use of plerixafor is superior to CY and growth factor for autologous hematopoietic stem cells mobilization.

scientific article published on 12 July 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

9 April 2018

http://europepmc.org/abstract/MED/20622909

Growth factor and patient-adapted use of plerixafor is superior to CY and growth factor for autologous hematopoietic stem cells mobilization. (English)

1 reference

Europe PubMed Central

PubMed publication ID

9 April 2018

http://europepmc.org/abstract/MED/20622909

1 reference

based on heuristic

inferred from title

7

1 reference

Europe PubMed Central

PubMed publication ID

9 April 2018

http://europepmc.org/abstract/MED/20622909

author name string

L J Costa

1

1 reference

Europe PubMed Central

PubMed publication ID

9 April 2018

http://europepmc.org/abstract/MED/20622909

A N Miller

2

1 reference

Europe PubMed Central

PubMed publication ID

9 April 2018

http://europepmc.org/abstract/MED/20622909

E T Alexander

3

1 reference

Europe PubMed Central

PubMed publication ID

9 April 2018

http://europepmc.org/abstract/MED/20622909

K R Hogan

4

1 reference

Europe PubMed Central

PubMed publication ID

9 April 2018

http://europepmc.org/abstract/MED/20622909

M Shabbir

5

1 reference

Europe PubMed Central

PubMed publication ID

9 April 2018

http://europepmc.org/abstract/MED/20622909

C Schaub

6

1 reference

Europe PubMed Central

PubMed publication ID

9 April 2018

http://europepmc.org/abstract/MED/20622909

language of work or name

0 references

publication date

12 July 2010

1 reference

Europe PubMed Central

PubMed publication ID

9 April 2018

http://europepmc.org/abstract/MED/20622909

Bone Marrow Transplantation

1 reference

Europe PubMed Central

PubMed publication ID

9 April 2018

http://europepmc.org/abstract/MED/20622909

46

1 reference

Europe PubMed Central

PubMed publication ID

9 April 2018

http://europepmc.org/abstract/MED/20622909

4

1 reference

Europe PubMed Central

PubMed publication ID

9 April 2018

http://europepmc.org/abstract/MED/20622909

523-528

1 reference

Europe PubMed Central

PubMed publication ID

9 April 2018

http://europepmc.org/abstract/MED/20622909

https://scigraph.springernature.com/pub.10.1038/bmt.2010.170

0 references

High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.170

21 January 2018

Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.170

21 January 2018

Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.170

21 January 2018

High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.170

21 January 2018

Comparison of peripheral blood progenitor cell mobilization in patients with multiple myeloma: high-dose cyclophosphamide plus GM-CSF vs G-CSF alone.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.170

21 January 2018

Comparison of high-dose CY and growth factor with growth factor alone for mobilization of stem cells for transplantation in patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.170

21 January 2018

Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.170

21 January 2018

Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.170

21 January 2018

Prediction of mobilisation failure in patients with non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.170

21 January 2018

Pharmacokinetics and pharmacodynamics of plerixafor in patients with non-Hodgkin lymphoma and multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.170

21 January 2018

A pharmacokinetic-pharmacodynamic model for the mobilization of CD34+ hematopoietic progenitor cells by AMD3100.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.170

21 January 2018

Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantatio

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.170

21 January 2018

Safety and efficacy assessment of plerixafor in patients with multiple myeloma proven or predicted to be poor mobilizers, including assessment of tumor cell mobilization.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.170

21 January 2018

Treatment with plerixafor in non-Hodgkin's lymphoma and multiple myeloma patients to increase the number of peripheral blood stem cells when given a mobilizing regimen of G-CSF: implications for the heavily pretreated patient

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.170

21 January 2018

Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.170

21 January 2018

Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.170

21 January 2018

A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.170

7 January 2021

based on heuristic

inferred from DOI database lookup

Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.170

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparable engraftment kinetics following peripheral-blood stem-cell infusion mobilized with granulocyte colony-stimulating factor with or without cyclophosphamide in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.170

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized cross-over trial of progenitor-cell mobilization: high-dose cyclophosphamide plus granulocyte colony-stimulating factor (G-CSF) versus granulocyte-macrophage colony-stimulating factor plus G-CSF.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.170

7 January 2021

based on heuristic

inferred from DOI database lookup

Cyclophosphamide Mobilization Does Not Improve Outcome in Patients Receiving Stem Cell Transplantation for Multiple Myeloma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.170

7 January 2021

based on heuristic

inferred from DOI database lookup

Purging of autologous peripheral-blood stem cells using CD34 selection does not improve overall or progression-free survival after high-dose chemotherapy for multiple myeloma: results of a multicenter randomized controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.170

7 January 2021

based on heuristic

inferred from DOI database lookup

Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.170

7 January 2021

based on heuristic

inferred from DOI database lookup

Development and validation of a decision-making algorithm to guide the use of plerixafor for autologous hematopoietic stem cell mobilization.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.170

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/BMT.2010.170

1 reference

Europe PubMed Central

PubMed publication ID

9 April 2018

http://europepmc.org/abstract/MED/20622909

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

9 April 2018

http://europepmc.org/abstract/MED/20622909

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51680781&oldid=1455500680"